申请人:Acuitas Therapeutics, Inc.
公开号:US20160376224A1
公开(公告)日:2016-12-29
Compounds are provided having the following structure:
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R
1a
, R
1b
, R
2a
, R
2b,
R
3a
, R
3b
, R
4a
, R
4b
, R
5
, R
6
, R
7
, R
8
, R
9
, L
1
, L
2
, G
1
, G
2
, G
3
, a, b, c and d are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
提供具有以下结构的化合物:或其药用可接受的盐、互变异构体或立体异构体,其中R1a、R1b、R2a、R2b、R3a、R3b、R4a、R4b、R5、R6、R7、R8、R9、L1、L2、G1、G2、G3、a、b、c和d如本文所定义。还提供了将这些化合物用作脂质纳米粒子配方的组分以传递治疗剂、包含这些化合物的组合物以及其使用和制备方法。